Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Total marrow and lymphoid irradiation (2000 cGy) together with cyclophosphamide and etoposide prior to allogeneic hematopoietic cell transplantation is an effective regimen for Relapsed/Refractory leukemia, with low non-relapse mortality

View Full Paper
Ask AI
Bookmark
Share

Authors

JPJoycelynne PalmerYWYan WangBBBrian Ball

Discussion

Loading...

Member takes

Overview

Phase 2 trial shows reduced non-relapse mortality and improved overall survival in patients with relapsed/refractory leukemia after total marrow and lymphoid irradiation with chemotherapy.

Key Points

  • Overall survival was 47.3% among survivors after treatment for relapsed/refractory leukemia, with low toxicity.
  • Ninety-eight patients achieved a complete remission after allogeneic hematopoietic cell transplantation, indicating treatment efficacy.
  • This assessment utilized a single-arm phase 2 trial with conditioning regimen involving total marrow and lymphoid irradiation.
  • The finding highlights the potential benefits of a 2000 cGy irradiation regimen with minimised acute and chronic graft versus host disease.

Cite This Study

Palmer et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3e4https://doi.org/10.1182/blood-2025-2441
View Full Paper
Ask AI
Bookmark
Share